138 related articles for article (PubMed ID: 30407148)
41. Evaluation of the carcinogenic potential of clofibrate in the rasH2 mouse.
Nesfield SR; Clarke CJ; Hoivik DJ; Miller RT; Allen JS; Selinger K; Santostefano MJ
Int J Toxicol; 2005; 24(5):301-11. PubMed ID: 16257850
[TBL] [Abstract][Full Text] [Related]
42. Toxicology and carcinogenesis studies of 1-bromopropane (CAS No. 106-94-5) in F344/N rats and B6C3F1 mice (inhalation studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2011 Aug; (564):1-190. PubMed ID: 21921963
[TBL] [Abstract][Full Text] [Related]
43. Spontaneous tumors of 2000 Wistar TNO/W.70 rats in two-year carcinogenicity studies.
Bomhard E; Karbe E; Loeser E
J Environ Pathol Toxicol Oncol; 1986; 7(1-2):35-52. PubMed ID: 3795013
[TBL] [Abstract][Full Text] [Related]
44. Comparison of the Class Effects of Antisense Oligonucleotides in CByB6F1-Tg(HRAS)2Jic and CD-1 Mice.
Kim TW; Papagiannis CN; Zwick LS; Engelhardt JA; Hoffmaster CM; Post NM; Matson JE; Hsiao JA; Burel SA; Henry SP
Toxicol Pathol; 2019 Jan; 47(1):82-92. PubMed ID: 30585133
[TBL] [Abstract][Full Text] [Related]
45. Transgene stability and features of rasH2 mice as an animal model for short-term carcinogenicity testing.
Suemizu H; Muguruma K; Maruyama C; Tomisawa M; Kimura M; Hioki K; Shimozawa N; Ohnishi Y; Tamaoki N; Nomura T
Mol Carcinog; 2002 May; 34(1):1-9. PubMed ID: 12112317
[TBL] [Abstract][Full Text] [Related]
46. Current status and use of short/medium term models for carcinogenicity testing of pharmaceuticals--scientific perspective.
Storer RD
Toxicol Lett; 2000 Mar; 112-113():557-66. PubMed ID: 10720780
[TBL] [Abstract][Full Text] [Related]
47. Regulatory Forum Commentary* Counterpoint: Dose Selection for Tg.rasH2 Mouse Carcinogenicity Studies.
Darbes J; Sistare FD; DeGeorge JJ
Toxicol Pathol; 2015 Jul; 43(5):621-7. PubMed ID: 26047967
[TBL] [Abstract][Full Text] [Related]
48. Possible mechanism on enhanced carcinogenesis of genotoxic carcinogens and unsolved mechanisms on lesser carcinogenic susceptibility to some carcinogens in rasH2 mice.
Mitsumori K
J Toxicol Sci; 2003 Dec; 28(5):371-83. PubMed ID: 14746341
[TBL] [Abstract][Full Text] [Related]
49. Toxicology and carcinogenesis studies of propargyl alcohol (CAS No. 107-19-7) in F344/N rats and B6C3F1 mice (inhalation studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2008 Sep; (552):1-172. PubMed ID: 18974778
[TBL] [Abstract][Full Text] [Related]
50. Rapid carcinogenicity testing system with transgenic mice harboring human prototype c-HRAS gene.
Yamamoto S; Hayashi Y; Mitsumori K; Nomura T
Lab Anim Sci; 1997 Apr; 47(2):121-6. PubMed ID: 9150488
[TBL] [Abstract][Full Text] [Related]
51. Interlaboratory comparison of the CB6F1-Tg rasH2 rapid carcinogenicity testing model.
Maronpot RR; Mitsumori K; Mann P; Takaoka M; Yamamoto S; Usui T; Okamiya H; Nishikawa S; Nomura T
Toxicology; 2000 May; 146(2-3):149-59. PubMed ID: 10814847
[TBL] [Abstract][Full Text] [Related]
52. Body weight-tumor incidence correlations in long-term rodent carcinogenicity studies.
Haseman JK; Young E; Eustis SL; Hailey JR
Toxicol Pathol; 1997; 25(3):256-63. PubMed ID: 9210256
[TBL] [Abstract][Full Text] [Related]
53. Progression of Serosal Vascular Proliferative Lesions to Hemangiosarcomas in the Uterus of the 26-Week Tg.rasH2 Mice Carcinogenicity Studies.
Paranjpe MG; Belich JL; Richardson DR; Vidmar T; Mann PC; McKeon ME; Elbekai RH
Int J Toxicol; 2017 Jan; 36(1):29-34. PubMed ID: 27440821
[TBL] [Abstract][Full Text] [Related]
54. Carcinogenicity assessment of baricitinib in Tg.rasH2 mice and Sprague-Dawley (Crl:CD) rats.
Carfagna M; Cannady E; Ryan T; Herman J; Truex L; Narwani K; Sullivan J
Regul Toxicol Pharmacol; 2018 Feb; 92():458-471. PubMed ID: 29203403
[TBL] [Abstract][Full Text] [Related]
55. Spontaneous and chemically induced proliferative lesions in Tg.AC transgenic and p53-heterozygous mice.
Mahler JF; Flagler ND; Malarkey DE; Mann PC; Haseman JK; Eastin W
Toxicol Pathol; 1998; 26(4):501-11. PubMed ID: 9715509
[TBL] [Abstract][Full Text] [Related]
56. The Trp53 hemizygous mouse in pharmaceutical development: points to consider for pathologists.
Floyd E; Mann P; Long G; Ochoa R
Toxicol Pathol; 2002; 30(1):147-56. PubMed ID: 11890468
[TBL] [Abstract][Full Text] [Related]
57. Alternative mouse models for carcinogenicity assessment: industry use and issues with pathology interpretation.
Long GG; Morton D; Peters T; Short B; Skydsgaard M
Toxicol Pathol; 2010 Jan; 38(1):43-50. PubMed ID: 19915137
[TBL] [Abstract][Full Text] [Related]
58. Use of transgenic animals for carcinogenicity testing: considerations and implications for risk assessment.
Gulezian D; Jacobson-Kram D; McCullough CB; Olson H; Recio L; Robinson D; Storer R; Tennant R; Ward JM; Neumann DA
Toxicol Pathol; 2000; 28(3):482-99. PubMed ID: 10862569
[TBL] [Abstract][Full Text] [Related]
59. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
60. A 28-day oral gavage toxicity study of 3-monochloropropane-1,2-diol (3-MCPD) in CB6F1-non-Tg rasH2 mice.
Lee BS; Park SJ; Kim YB; Han JS; Jeong EJ; Moon KS; Son HY
Food Chem Toxicol; 2015 Dec; 86():95-103. PubMed ID: 26434797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
